ArticleESC heart failure2025
Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardioimmunologic response patterns after an acute heart failure event: Design and first results of AHF-ImmunoCS.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe have previously shown that patients who develop heart-reactive antibodies (HRAs) de novo after a heart failure (HF) hospitalization are at increased risk of adverse outcomes, lending weight to the hypothesis that B cells may play a pivotal role in HF progression. We therefore aim to further elucidate the adaptive immune response to an acute HF event, with a particular focus on the factors that lead to incident HRAs and their relation to worsening cardiac function and prognosis. METHODS AND
resultsThe Acute Heart Failure Immunomonitoring Cohort Study (AHF-ImmunoCS) is a prospective monocentric cohort study. Patients are enrolled consecutively during hospitalization for AHF and undergo detailed phenotyping at baseline and at 6-week, 6-, 12- and 18-month follow-up visits. Patient sera are screened for HRAs by immunofluorescence testing (IFT) as well as by using defined cardiac antigens immobilized on beads. By 31 December 2023, we had included 259: 38% women, mean age 72 (SD 13) years, 37% de novo HF, median left ventricular ejection fraction 50 (quartiles 35, 56) %. Preliminary data of the first 59 patients (42% women, mean 72 (14) years) showed that 80% of patients exhibiting seroconversion had done so within 6 weeks.
conclusionAHF-ImmunoCS is enrolling a representative cohort of HF patients. Our preliminary data confirm that seroconversion to HRAs occurs early after hospitalization for HF in a subgroup of patients. The full study can be expected to clarify how changes in HRA profiles relate to prognosis and may pave the way for novel immunotherapeutic approaches to acute heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.